Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
已完成
4
40.0%
招募中
4
40.0%
终止
2
20.0%
暂无批准数据
- ORIC Pharmaceuticals shares surged 36.3% after presenting encouraging clinical data for ORIC-944 in metastatic castration-resistant prostate cancer at the J.P. Morgan Healthcare Conference. - The company strengthened its strategic position through collaborations with major pharmaceutical partners including Pfizer, Bayer, and Johnson & Johnson, particularly evaluating enozertinib with J&J's amivantamab. - ORIC-944 is advancing toward potential Phase 3 trials in 2026, while ORIC-114 continues Phase 1b development with Janssen's involvement underscoring clinical relevance. - Despite positive momentum, analysts note the company faces ongoing challenges including continuing losses of approximately $135.27 million and reliance on successful trial progression.
- ORIC Pharmaceuticals published peer-reviewed research in Cancer Research detailing enozertinib, a highly selective, brain-penetrant EGFR inhibitor targeting exon 20 mutations in non-small cell lung cancer. - Preclinical data demonstrates enozertinib's exceptional kinome selectivity, strong potency, and anti-tumor activity across atypical EGFR mutant contexts, including intracranial lung cancer models. - A patient case study showed enozertinib achieved sustained complete response of both systemic and brain metastases in NSCLC with EGFR exon 20 insertion mutation. - The drug represents the only EGFR exon 20 inhibitor to demonstrate complete systemic and CNS responses in a patient with untreated, active brain metastases.
- ORIC Pharmaceuticals completed the dose exploration portion of its Phase 1b trial for ORIC-944, a PRC2 inhibitor, in combination with AR inhibitors for metastatic castration-resistant prostate cancer. - The trial demonstrated strong efficacy signals with 55% PSA50 response rate and 20% PSA90 response rate, alongside rapid ctDNA reductions in 76% of patients. - Both combination regimens with apalutamide and darolutamide showed favorable safety profiles compatible with long-term dosing, with most adverse events being Grade 1 or 2. - The company plans to announce dose optimization data in Q1 2026 and initiate its first global Phase 3 registrational trial in the first half of 2026.
- ORIC Pharmaceuticals has advanced its lead cancer drug candidates ORIC-114 and ORIC-944 into Phase 1b studies, with ORIC-944 showing promising efficacy and safety results in metastatic castration-resistant prostate cancer patients. - The company has established strategic collaborations with major pharmaceutical companies including Pfizer, Bayer, and Johnson & Johnson, reinforcing external confidence in ORIC's research pipeline. - Recent Phase 1b trial data for ORIC-944 demonstrated robust antitumor activity and favorable safety profile in heavily pretreated prostate cancer patients, with significant PSA and ctDNA responses. - Despite clinical progress, ORIC remains unprofitable with no revenue and rising net losses, with dose optimization results expected in early 2026 representing a critical upcoming catalyst.
- ORIC Pharmaceuticals has appointed Kevin Brodbeck, PhD, as Chief Technical Officer to support the company's transition into late-stage clinical development. - The appointment reflects ORIC's preparation for potential Phase 3 trials of ORIC-944 and enozertinib starting in 2026. - Brodbeck brings over 25 years of experience in technical operations, CMC, and regulatory activities across pharmaceutical development and commercialization. - ORIC's clinical pipeline includes ORIC-944 for prostate cancer and enozertinib for multiple genetically defined cancers targeting resistance mechanisms.
- Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts. - Companies are shifting from broad R&D portfolios to focused pipeline optimization, with firms like Shattuck Labs and Relay Therapeutics narrowing their therapeutic focus to core projects with highest potential returns. - The layoffs reflect strategic responses to investor pressure for capital discipline, post-pandemic demand shifts, and the need to extend cash reserves while maintaining progress on lead clinical programs. - Industry consolidation and increased outsourcing to contract research organizations are driving operational realignment, as companies seek to reduce overhead costs and access specialized expertise without maintaining high-cost facilities.
- ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC). - The company entered a clinical trial collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. - ORIC anticipates seven data readouts across ORIC-114 and ORIC-944 programs in the next 18 months, potentially leading to registrational trials in 2025 and 2026.
- Unicycive Therapeutics' OLC shows promise in treating hyperphosphatemia by reducing pill burden and adverse events, potentially gaining FDA approval by June 2025. - ORIC Pharmaceuticals' ORIC-944, combined with apalutamide, demonstrates significant PSA level decreases in metastatic castration-resistant prostate cancer patients. - Durability of ORIC-944 responses, with some patients maintaining PSA90 responses for 38 weeks, supports confidence in Oric Pharmaceuticals' strategic advancements. - H.C. Wainwright analyst Ed Arce maintains a Buy rating on Unicycive with a $4.00 price target, while Robert Burns reiterates a Buy rating on Oric with a $21.00 target.
- ORIC Pharmaceuticals presented preclinical data on ORIC-944, a PRC2 inhibitor, showing potential as a best-in-class treatment for prostate cancer in combination with AR inhibitors. - The company also unveiled data for ORIC-613, a PLK4 inhibitor, demonstrating synthetic lethality in TRIM37-high tumor models, suggesting its potential as a treatment option. - ORIC-944 exhibits strong potency and a favorable clinical half-life, positioning it as a promising candidate for prostate cancer therapy. - ORIC-613 has shown potent and selective inhibition of PLK4, leading to tumor regressions in preclinical studies, highlighting its therapeutic potential.
